GLS

Glenmark Life Sciences Share PriceGlenmark Life Sciences

₹635.6
-4.7 (-0.73%)
As on 06 December, 2023 | 03:31 BSE: 543322 NSE: GLSISIN: INE03Q201024

Glenmark Life Sciences Performance

Day Range

  • Low 630.35
  • High 649.90
₹ 635.6

52 Week Range

  • Low 370.00
  • High 675.00
₹ 635.6
  • Open Price640.10
  • Previous Close640.30
  • Volume79331

Start SIP in Glenmark Life Sciences

Start SIP

Glenmark Life Sciences Share Price

  • Over 1 Month 2.43%
  • Over 3 Month 0.61%
  • Over 6 Month 18.34%
  • Over 1 Year 45.61%

Glenmark Life Sciences Key Statistics

P/E Ratio 15.4
PEG Ratio 0.7
Market Cap Cr 7,788
Price to Book Ratio 3.6
EPS 38.1
Dividend 6.8
Relative Strength Index 55.67
Money Flow Index 56.93
MACD Signal 1.23
Average True Range 11.04

Glenmark Life Sciences Investment Rating

  • Master Rating:
  • Glenmark Life Sciences has an operating revenue of Rs. 2,335.86 Cr. on a trailing 12-month basis. An annual revenue growth of 2% is not great, Pre-tax margin of 29% is great, ROE of 21% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 15% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 131 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 595578621541509490514
Operating Expenses Qtr Cr 428385415395366343372
Operating Profit Qtr Cr 167193206145144147142
Depreciation Qtr Cr 13131211101010
Interest Qtr Cr 0000000
Tax Qtr Cr 40475136373839
Net Profit Qtr Cr 11913514610510710999
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 2,1902,138
Operating Expenses Annual Cr 1,5191,507
Operating Profit Annual in Cr 642616
Depreciation Cr 4238
Interest Annual Cr 128
Tax Annual Cr 162146
Net Profit Annual Cr 467419
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 313598
Cash from Investing Activity Annual Cr -154-122
Cash from Financing Annual Activity Cr -388-79
Net Cash Flow Annual Cr -228397
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 2,1382,054
Fixed Assets Annual Cr 842687
Total Non Current Assets Annual Cr 852706
Total Current Assets Annual Cr 1,8501,765
Total Assets Annual Cr 2,7022,471
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 175168
ROE Annual % 2220
ROCE Annual % 2928
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 3130
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr
Operating Expenses Qtr Cr
Operating Profit Qtr Cr
Depreciation Qtr Cr
Interest Qtr Cr
Tax Qtr Cr
Net Profit Qtr Cr
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr
Operating Expenses Annual Cr
Operating Profit Annual in Cr
Depreciation Cr
Interest Annual Cr
Tax Annual Cr
Net Profit Annual Cr
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr
Cash from Investing Activity Annual Cr
Cash from Financing Annual Activity Cr
Net Cash Flow Annual Cr
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr
Fixed Assets Annual Cr
Total Non Current Assets Annual Cr
Total Current Assets Annual Cr
Total Assets Annual Cr
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs
ROE Annual %
ROCE Annual %
Total Debt to Total Equity Annual --
EBDIT Annual Margin %

Glenmark Life Sciences Technicals

EMA & SMA

Current Price
₹635.6
-4.7 (-0.73%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹630.39
  • 50 Day
  • ₹627.49
  • 100 Day
  • ₹612.67
  • 200 Day
  • ₹575.04
  • 20 Day
  • ₹629.83
  • 50 Day
  • ₹627.75
  • 100 Day
  • ₹629.34
  • 200 Day
  • ₹554.82

Glenmark Life Sciences Resistance and Support

PIVOT
₹638.62
Resistance
First Resistance 646.88
Second Resistance 658.17
Third Resistance 666.43
RSI 55.67
MFI 56.93
MACD Single Line 1.23
MACD 2.37
Support
First Resistance 627.33
Second Resistance 619.07
Third Resistance 607.78

Glenmark Life Sciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 81,998 4,910,860 59.89
Week 111,289 8,005,018 71.93
1 Month 118,760 8,572,097 72.18
6 Month 219,283 13,172,335 60.07

Glenmark Life Sciences Result Highlights

Glenmark Life Sciences Synopsis

NSE-Medical-Ethical Drugs

Glenmark Life Scienc belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 2161.22 Cr. and Equity Capital is Rs. 24.51 Cr. for the Year ended 31/03/2023. Glenmark Life Sciences Ltd. is a Public Limited Listed company incorporated on 23/06/2011 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L74900PN2011PLC139963 and registration number is 139963.
Market Cap 7,788
Sales 2,336
Shares in Float 2.08
No of funds 79
Yield 6.84
Book Value 3.64
U/D Vol ratio 1.7
LTDebt / Equity
Alpha 0.13
Beta 0.68

Glenmark Life Sciences

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 82.85%82.85%82.85%82.85%
Mutual Funds 0.38%0.52%
Insurance Companies 0.15%0.07%
Foreign Portfolio Investors 4.39%3.27%3.28%4.45%
Financial Institutions/ Banks
Individual Investors 9.21%10.02%10.87%9.78%
Others 3.02%3.34%3%2.85%

Glenmark Life Sciences Management

Name Designation
Mr. Glenn Saldanha Chairman & Non-Exe.Director
Dr. Yasir Rawjee Managing Director & CEO
Mr. Vinod Naik Executive Director
Mr. V S Mani Non Executive Director
Mr. Sridhar Gorthi Independent Director
Mrs. Manju Agarwal Independent Director
Mr. Taruvai Laxminarayanan Easwar Independent Director
Ms. Gita Nayyar Independent Director

Glenmark Life Sciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Glenmark Life Sciences Corporate Action

Date Purpose Remarks
2023-10-20 Quarterly Results
2023-10-09 Interim Dividend
2023-07-21 Quarterly Results
2023-04-27 Audited Results
2023-03-16 Interim Dividend
Date Purpose Remarks
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend

Glenmark Life Sciences MF Shareholding

Name Amount(cr)
Union Small Cap Fund Regular Growth 2,869
Union Flexi Cap Fund Growth 1,621
Nippon India Nifty Smallcap 250 Index Fund Reg Gr 719
Union Tax saver (ELSS) Fund Growth 695
Union Multicap Fund Regular Growth 618

Glenmark Life Sciences FAQs

What is Share Price of Glenmark Life Sciences ?

Glenmark Life Sciences share price is ₹635 As on 06 December, 2023 | 03:17

What is the Market Cap of Glenmark Life Sciences ?

The Market Cap of Glenmark Life Sciences is ₹7787.8 Cr As on 06 December, 2023 | 03:17

What is the P/E ratio of Glenmark Life Sciences ?

The P/E ratio of Glenmark Life Sciences is 15.4 As on 06 December, 2023 | 03:17

What is the PB ratio of Glenmark Life Sciences ?

The PB ratio of Glenmark Life Sciences is 3.6 As on 06 December, 2023 | 03:17

Q2FY23